Abstract
Overview
Introduction
Major Depressive Disorder (MDD) is estimated to affect over 34 million
individuals yearly across the seven major markets. Only a fraction of this
patient population is treated adequately, resulting in lost productivity,
unnecessary patient suffering and unfulfilled revenue potential for
manufacturers.
Scope
- Analysis of a survey of 180 prescribing physicians in the seven major
markets as well as in-depth interviews with Key Opinion Leaders
- Detailed treatment trees showing the prevalence, diagnosis and treatment
rates of Major Depressive Disorder across the seven major markets
- Discussion of the influence of treatment guidelines on physicians
- Insight into diagnostic and therapeutic unmet needs, and recommendations
to aid market penetration and maximize prescription rates
Highlights
Individuals with milder forms of MDD are unlikely to present to physicians.
Across the seven major markets, only around a half of individuals are then
accurately diagnosed at first presentation.
Despite safety concerns surrounding some of the newer antidepressants, the
prescribing habits of physicians have changed little, suggesting that the
concerns may have been over-hyped.
Cymbalta (duloxetine) is at risk of being seen as a 'me-too' SNRI.
Datamonitor's primary research suggests that by focusing on the treatment of
painful physical symptoms of depression, Lilly might be missing the drug's
more significant advantages.
Reasons to Purchase
- Identify which healthcare professional is responsible for treating
patients with differing severities of MDD, allowing for efficient product
marketing
- Ascertain the preferred and most frequently prescribed drugs for first and
second-line therapy, gaining key insight into the competitive landscape
- Identify unmet needs to enhance development and market penetration
strategies of MDD drugs
View Cart
